Ascendis Pharma (Nasdaq:ASND) - Cotización, noticias y análisis

Resumen de acción ASND

Ascendis Pharma A/S, empresa biofarmacéutica, se centra en el desarrollo de terapias para necesidades médicas no cubiertas.

Acerca de la empresa

ASND fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	6/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Recompensas

Cotiza un 82.1% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 57.75%

Análisis de riesgos

Patrimonio neto negativo

Tiene menos de 1 año de cash runway

Competidores de Ascendis Pharma A/S

Rhythm Pharmaceuticals

NasdaqGM:RYTM

US$2.4b

Global Blood Therapeutics

NasdaqGS:GBT

US$4.6b

Arcellx

NasdaqGS:ACLX

US$2.8b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$1.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Ascendis Pharma
Historical stock prices
Current Share Price	US$142.10
52 Week High	US$161.00
52 Week Low	US$66.03
Beta	0.51
1 Month Change	-2.01%
3 Month Change	5.95%
1 Year Change	81.34%
3 Year Change	4.25%
5 Year Change	27.58%
Change since IPO	654.65%

Noticias y actualizaciones recientes

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Apr 05

Recent updates

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Oct 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Jun 27

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

May 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Feb 18

Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?

Sep 24

Ascendis Pharma: TransCon CNP Data Coming Q4

Sep 15

Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH

Aug 31

Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa

Aug 11

Ascendis Pharma: Institutional Buying Values Dutch Biotech Best-Now Cap-Gain Prospect

Aug 03

Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money

Jun 10

Ascendis Pharma: Biotech Bear Provides Attractive Entry Point

May 09

Ascendis: Institutional Buying Activity Now Seen As Good Value By Market-Makers

Apr 29

Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 51% Above Its Share Price

Feb 24

Is Ascendis Pharma (NASDAQ:ASND) In A Good Position To Invest In Growth?

Jan 07

Ascendis: Danish Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Dec 30

Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 97% Above Its Share Price

Sep 24

Ascendis Pharma: A Promising Platform And A Rich Valuation

Sep 10

We're Hopeful That Ascendis Pharma (NASDAQ:ASND) Will Use Its Cash Wisely

Aug 12

Best Biotech Stock (Now): Ascendis Pharma, Where Best = Capital Gain ODDS Next 3 Months

Jun 30

Rentabilidad de los accionistas

	ASND	US Biotechs	Mercado US
7D	0.4%	-2.5%	-3.2%
1Y	81.3%	-3.7%	19.3%

Rentabilidad vs. Industria: ASND superó al sector US Biotechs , que obtuvo un rendimiento del 6.8% el año pasado.

Rentabilidad vs. Mercado: ASND superó al mercado US, que obtuvo un rendimiento del 19.7% el año pasado.

Volatilidad de los precios

Is ASND's price volatile compared to industry and market?
ASND volatility
ASND Average Weekly Movement	5.3%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: ASND no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ASND (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2006	879	Jan Mikkelsen	ascendispharma.com

Ascendis Pharma A/S, empresa biofarmacéutica, se centra en el desarrollo de terapias para necesidades médicas no cubiertas. Ofrece SKYTROFA para el tratamiento de pacientes con deficiencia de la hormona del crecimiento (GHD). La empresa también está desarrollando una cartera de tres productos candidatos independientes para enfermedades raras endocrinológicas en fase de desarrollo clínico, además de centrarse en el avance de candidatos terapéuticos oncológicos.

Resumen de fundamentos de Ascendis Pharma A/S

¿Cómo se comparan los beneficios e ingresos de Ascendis Pharma con su capitalización de mercado?
Estadísticas fundamentales de ASND
Capitalización bursátil	US$8.12b
Beneficios(TTM)	-US$512.83m
Ingresos (TTM)	US$284.11m

28.6x

Ratio precio-ventas (PS)

-15.8x

Ratio precio-beneficio (PE)

¿Está ASND sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ASND
Ingresos	€266.72m
Coste de los ingresos	€44.40m
Beneficio bruto	€222.32m
Otros gastos	€703.77m
Beneficios	-€481.45m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-8.43
Margen bruto	83.36%
Margen de beneficio neto	-180.51%
Ratio deuda/patrimonio	-374.4%

¿Cómo se ha desempeñado ASND a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ASND

Recompensas

Análisis de riesgos

Competidores de Ascendis Pharma A/S

NasdaqGM:RYTM

US$2.4b

NasdaqGS:GBT

US$4.6b

NasdaqGS:ACLX

US$2.8b

NasdaqGS:AGIO

US$1.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Executive VP notifies of intention to sell stock

Consensus estimates of losses per share improve by 17%

President notifies of intention to sell stock

President notifies of intention to sell stock

Recent updates

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Executive VP notifies of intention to sell stock

Consensus estimates of losses per share improve by 17%

President notifies of intention to sell stock

President notifies of intention to sell stock

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Consensus revenue estimates increase by 12%

Ascendis Pharma's Ambitious Vision 2030

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

President notifies of intention to sell stock

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

New major risk - Negative shareholders equity

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Consensus revenue estimates decrease by 11%

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Key Executive notifies of intention to sell stock

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Consensus revenue estimates increase by 24%

Independent Chairman notifies of intention to sell stock

New major risk - Financial position

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Consensus revenue estimates decrease by 14%

President notifies of intention to sell stock

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

President notifies of intention to sell stock

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH

President notifies of intention to sell stock

Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism

TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism